Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia

6 May 2022

Abstract excerpt

The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential metabolic precursors for nucleic acids, glycoproteins, and phospholipids. DHODH inhibitors (DHODHi) are clinically used for autoimmune diseases and are emerging as a novel class of anticancer agents, especially in acute myeloid leukemia (AML)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to HIV/AIDS drug development and treatment
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35514210
DOI: 10.15252/emmm.202115203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemiaPMID 35514210Read ↗

Inhibition of pyrimidine biosynthesis targets protein translation in AMLSemantic proximity Read ↗

Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia.Semantic proximity Read ↗

Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibitionSemantic proximity Read ↗

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSemantic proximity Read ↗

LncRNA BCYRN1 regulates mitochondrial MT-ND1/4/5 transcription via heavy strand promoter methylation to promote oxidative phosphorylation and proliferation in acute myeloid leukemiaSemantic proximity Read ↗

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis InhibitionSemantic proximity Read ↗

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Semantic proximity Read ↗

Identification and targeting of novel CDK9 complexes in acute myeloid leukemiaSemantic proximity Read ↗

Translation initiation factor eIF4F modifies the dexamethasone response in multiple myelomaSemantic proximity Read ↗

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.